Ngokwemiphumela emenyezelwe emhlanganweni waminyaka yonke we-ASCO wezi-2018, iCDK4/6 inhibitors pabociclib (Ibrance) kanye ne-cetuximab (Erbitux) kuhlangene ukwelashwa kwe-platinum-resistant kanye ne-HPV-independent recurrent/metastatic head kanye ne.